KZR-616 Shows Early Promise in Treatment of Active SLE
KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…